Terumo and Quirem Medical, a commercial stage Dutch medical technology company that focuses on radioembolization, have announced that Terumo has made an equity investment in Quirem Medical.
Dedicated venous stents can be effectively used to relieve outflow obstruction at one year following thrombotic disease in both the acute and chronic setting, according to the prize-winning research presented at the European Venous Forum (EVF; 2–4 July, Saint Petersburg, Russia). Prakash Saha, King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, said, however, that as deep venous reconstruction is challenging, complex cases may require reintervention or adjunctive procedures.
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
The first patient has been enrolled in ETNA-AF-Europe (Edoxaban treatment in routine clinical practice – atrial fibrillation – Europe), and ETNA-VTE-Europe (Edoxaban treatment in routine clinical practice – venous thromboembolism – Europe) has commenced.
Results of the landmark CATCH (Comparison of Acute Treatments in Cancer Haemostasis) study were published in The Journal of American Medical Association (JAMA), comparing innohep (tinzaparin), a low-molecular weight heparin (LMWH), with warfarin in patients with cancer-associated thrombosis.
BTG announced on 6 August 2015 that Health Canada has issued a notice of compliance approving polidocanol injectable foam (Varithena, BTG) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, above and below the knee.
A review of haemodynamics in stent development, published in Annals of Biomedical Engineering, suggests that the re-introduction of spiral flow after endovascular treatment for peripheral artery disease (PAD) may support endothelial function and increase patency rates.
Medtronic announced on 2 November 2015 the initiation of the REALITY Study (Directional atherectomy + drug-coated balloon to treat long, calcified femoropopliteal artery stenoses) to evaluate patient outcomes following adjunctive use of directional atherectomy and drug-coated balloon treatment of patients with symptomatic peripheral arterial disease in long, calcified lesions in the superficial femoral artery and/or popliteal artery. The study is sponsored and will be managed by VIVA Physicians, and will have multidisciplinary representation in leadership.
The first two patients have been enrolled in Cardiovascular Systems’ OPTIMIZE peripheral orbital atherectomy system study. Taking place in Europe, OPTIMIZE will evaluate the acute and long-term clinical outcomes of orbital atherectomy with adjunctive drug-coated balloon (DCB) angioplasty versus DCB angioplasty alone for treatment of peripheral artery disease.
Jotec has announced that since the worldwide market launch more than 500 patients have been successfully treated with the E-liac stent graft. According to the company, E-liac is an innovative stent graft system used not only for the endovascular treatment of aorto-iliac aneurysms but also for isolated iliac aneurysms to preserve blood flow into the internal iliac artery.
Endologix and TriVascular announced on 26 October that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. The transaction is valued at US$9.10 per TriVascular share, or a total of approximately US$211 million, based on Endologix’s closing stock price of US$13.81 per share on 23 October 2015.
Vascular Flow Technologies has announced the launch of its Spiral Flow PV Bypass Graft registry at the 31st annual Deutschen Gesellschaft für Gefäßmedezin (DGG) in Münster, Germany.
On 14 October 2015, Avinger announced that it has received 510(k) clearance from the FDA to commence US commercialisation of its Pantheris image-guided atherectomy system for the treatment of patients with peripheral arterial disease. Pantheris combines directional atherectomy with real-time, intravascular visualisation and is designed to empower physicians to precisely remove plaque from blocked arteries, while avoiding disruption of normal arterial wall structures.
The first two cases in the EffPac randomised clinical multicentre trial of its luminor 35 drug-eluting balloon system have been successfully performed, according to iVascular.
Avinger announced on 13 October 2015 interim six-month results for its VISION clinical trial. VISION is designed to evaluate the safety and effectiveness of the Pantheris system to perform directional atherectomy while for the first time ever allowing physicians to use real-time intravascular imaging to aid in the removal of plaque from diseased lower extremity arteries.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos